Literature DB >> 19356737

The NANC relaxation of the human ileal longitudinal and circular muscles is inhibited by MRS 2179, a P2 purinoceptor antagonist.

Sarolta Undi1, Rita Benko, Matyas Wolf, Laszlo Illenyi, Andras Vereczkei, Dezsö Kelemen, Laszlo Cseke, Zsolt Csontos, Ors Peter Horvath, Lorand Bartho.   

Abstract

AIMS: Functional innervation of the human small intestine may be different from that of experimental animals. These experiments set out to assess the mediating roles of P(2) purinoceptors in the non-adrenergic, non-cholinergic (NANC) relaxation of the human ileum longitudinal and circular muscles. MAIN
METHODS: In organ bath experiments NANC relaxations were evoked by electrical field stimulation (EFS). The relaxant effects of ATP and sodium nitroprusside were also examined. KEY
FINDINGS: In the longitudinal muscle, relaxation in response to EFS (2 or 10 Hz for 30 s) or the relaxant effect of exogenous ATP were strongly inhibited or abolished, respectively, by the P(2) purinoceptor antagonist MRS 2179 (10 microM). MRS 2179 had a smaller effect at 3 microM. The NANC relaxation was also inhibited by apamin (3 microM), but not by N(G)-nitro-L-arginine (100 microM), an inhibitor of nitric oxide synthesis. Both apamin (3 microM) and MRS 2179 (3 microM, a concentration below the effective range if administered alone) strongly inhibited the NANC response in preparations pretreated with the nitric oxide synthase inhibitor. NANC relaxations of the circular muscle were also inhibited by MRS 2179 (3-10 microM). SIGNIFICANCE: MRS 2179-sensitive P(2) purinoceptors play a mediating role the NANC relaxation in the ileal longitudinal and circular muscle. There seems to be a supra-additive relationship between the purinergic and nitrergic mechanisms in the longitudinal muscle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356737     DOI: 10.1016/j.lfs.2009.03.020

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  The impact of commercially available purinergic ligands on purinergic signalling research.

Authors:  J R Flanaghan; S J Roome
Journal:  Purinergic Signal       Date:  2011-10-27       Impact factor: 3.765

Review 2.  Purinergic neuromuscular transmission in the gastrointestinal tract; functional basis for future clinical and pharmacological studies.

Authors:  Marcel Jiménez; Pere Clavé; Anna Accarino; Diana Gallego
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 3.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.